The Rising Cost of Lung Cancer Therapies: What Are the Global Implications?

The Future Is Now: Pathology Is Going Digital

Histologic Evaluation of Lung Cancer Invasion: More Difficult Than Meets the Eye

Recurrence Remains a Risk Even for Patients Diagnosed via Screening

New Data Support Continued Use of IASLC Staging Model for Mesothelioma

Proposed Criteria for Tumor Invasion Align with Clinical Factors, Offer Better Predictability, Study Finds

TERAVOLT: Increased Risk of Morbidity for Patients with Lung Cancer and COVID-19 Drives Research Collaboration

Member Story: Dr. Noemi Reguart

Member Story: Suraj Samtani Bassarmal

Member Story: Dr. Shengxiang Ren

Member Story: Dr. Amy Moore

Member Stories: Dr. Ross Soo